COPENHAGEN, Denmark, Sept. 30, 2012 /CNW/ -
LEO Pharma has conducted the first truly large scale international study
informed by both qualitative and quantitative data to investigate the
impact of psoriasis
The findings reveal that feelings of restriction, isolation,
stigmatisation and anxiety are associated with a high impact on
patients' lives; and are more important than diagnosed symptom severity
Data from the Burden of Psoriasis patient research were presented this
weekend at the 21st EADV Congress in Prague, Czech Republic. The results from the research,
which included a quantitative online survey completed by 3,822 patients
with psoriasis, showed 73% of patients surveyed scored their psoriasis
as having a moderate to high impact on their lives.
To view the Multimedia News Release, please click:
People living with psoriasis experience flare-ups that can result in the
appearance of thick, red, scaly skin lesions on any part of their body. The skin is often sore and itchy ,[ 3], but the current study emphasizes that the psychological impact of
psoriasis can have an even greater impact on patients' everyday lives.
Factors analysed in the research included the influence of symptom
burden, healthcare professional (HCP) relationships, patient factors
and the psychosocial impact of psoriasis on how much the patient's
psoriasis "dictates how they live their life". Factors that were most strongly associated dealt with daily
activities, stigmatisation, isolation and anxiety. However, diagnosed
symptom severity was not a significant indicator.
Commenting on the research Dr Anthony Bewley, Whipps Cross University
Hospital & Barts & the London NHS Trust, UK, said, "The reality for
patients is that the reactions of other people, real or perceived, can
make life a real struggle. We need to ensure that we actively question
our patients about these issues, and modify management accordingly. We
plan further analysis of this comprehensive data set, which we believe
will help to individualise care".
"The physical, psychological and social effects of psoriasis can have a
serious impact on people's lives," said LEO Pharma President and CEO
Gitte P. Aabo. "To give people with psoriasis the best chance of
improving their quality of life, we need to address the issues that
affect them individually. The Burden of Psoriasis patient research will
help healthcare professionals learn more about the impact that
psoriasis has on peoples' lives and hence inform and help evolve the
way the disease is treated."
Bewley A, Ersser S, Hansen M, Pevac C. Psychosocial and symptomatic
burden of psoriasis for patients in Europe, the USA and Canada.
Abstract presented at: EADV Congress, Prague, 27 - 30 September 2012
(ID number PRA12-0920).
Basavaraj KH, Navya MA, Rashmi R. Stress and quality of life in
psoriasis: an update. Int J Dermatol 2011;50:783-92.
A.D.A.M. Medical Encyclopedia. Psoriasis. (Accessed May, 2012, at http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001470/.)
SOURCE: LEO Pharma Inc.
For further information:
Helga Heyn, LEO Pharma, Tel: +45-26-29-41-97, E-mail: firstname.lastname@example.org; Olivia Mosley, Burson-Marsteller, Tel: +44-207-300-6257, E-mail: email@example.com